Association between Impella device support and elevated rates of gout flares: a retrospective propensity-matched study

TL;DR

This study finds that patients using the Impella heart support device experience significantly higher gout flare rates compared to those who do not use it.

Contribution

The study is the first to identify a potential link between Impella device support and increased gout flare rates.

Findings

Impella-supported patients had a significantly higher prevalence of gout flares (30.9%) compared to non-Impella patients (5.3%).

Propensity-matched analysis confirmed a higher risk of gout flares in Impella patients (30.9% vs. 7.1%).

Impella use was associated with increased gout flare risk across multiple statistical models (ORs of 8.07, 5.83, and 4.21).

Abstract

Impella is an advanced ventricular assist device frequently used as a bridge to heart transplantation. The association of Impella with increased rates of gout flares has not been studied. Our primary aim is to determine the rates of gout flares in patients on Impella support.

A retrospective study was conducted between January 2017 and September 2022 involving all patients who underwent heart transplantation. The cohort was divided into two groups based on Impella support for statistical analysis. In patients receiving Impella support, outcome measures were compared based on the development of gout flares. 1:1 nearest neighbor propensity match, as well as inverse propensity of treatment weighted analyses, were performed to explore the causal relationship between impella use and gout flare in our study population.

Our analysis included 213 patients, among which 42 (19.71%) patients were supported by Impella. Impella and non-Impella groups had similar age, race, and BMI, but more males were in the Impella group. Gout and chronic kidney disease were more prevalent in Impella-supported patients, while coronary artery disease was less common. The prevalence of gout flare was significantly higher in Impella patients (30.9% vs. 5.3%). 42 Impella-supported patients were matched with 42 patients from the non-impella group upon performing a 1:1 propensity matching. Impella-supported patients were noted to have a significantly higher risk of gout flare (30.9% vs. 7.1%, SMD = 0.636), despite no significant difference in pre-existing gout history and use of anti-gout medications. Impella use was associated with a significantly increased risk of gout flare in unadjusted (OR 8.07), propensity-matched (OR 5.83), and the inverse propensity of treatment-weighted analysis (OR 4.21).

Our study is the first to identify the potential association between Impella support and increased rates of gout flares in hospitalized patients. Future studies are required to confirm this association and further elucidate the biological pathways. It is imperative to consider introducing appropriate measures to prevent and promptly manage gout flares in Impella-supported patients.

The online version contains supplementary material available at 10.1186/s41927-024-00380-z.

Figures